Seegene Introduces CURECATM: A Revolutionary Solution for PCR Automation
Seegene's Innovative CURECATM: Redefining PCR Automation
In a remarkable leap forward in the field of molecular diagnostics, Seegene Inc., a recognized leader in the industry, has introduced CURECATM, a revolutionary platform designed to streamline the entire PCR diagnostic workflow. This innovative system was presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 event, held in Vienna, Austria, where it drew considerable attention from industry professionals.
The Concept Behind CURECATM
CURECATM embodies a fully modular design that significantly enhances the automation of pre-treatment processes for a variety of PCR specimen types, including stool, urine, blood, and sputum. This cutting-edge solution aims to integrate seamlessly into unattended laboratory workflows, showcasing a versatility that caters to diverse diagnostics needs.
During the ESCMID event, over 2,300 attendees, including leading figures from various countries, flocked to Seegene's booth to observe the concept video of CURECATM, highlighting its potential to automate the complete PCR diagnostic process. The excitement was palpable, as many industry experts expressed their anticipation of a system that could minimize human error associated with manual handling.
Addressing Market Needs
One of the standout features of CURECATM is its Customizable Pre-treatment System (CPS), which focuses on automating the loading and processing of primary sample tubes. This system is optimized for a range of diagnostic fields, including molecular diagnostics and clinical chemistry. Young-Seag Baeg, Seegene's Head of Strategy and Planning, emphasized how the CPS can transform laboratory operations, particularly in automating time-consuming manual tasks that currently rely on skilled professionals.
Feedback from attendees at the ESCMID event indicated high expectations for how CURECATM could revolutionize molecular diagnostics. Many noted the potential for improved turnaround times in test results and enhanced daily operations, particularly in handling specimens for sexually transmitted infections (STIs), which are known for their complex and labor-intensive testing procedures.
Modular and Configurable Solutions
Following the pre-treatment stage, CURECATM’s modular architecture allows laboratories the flexibility to perform nucleic acid extraction, PCR setup, amplification, and results analysis. The inclusion of the Primary Sample Aliquot System (PAS) provides an alternative for loading samples directly without prior processing, catering to the varying needs of different laboratories.
Seegene’s approach with CURECATM encapsulates a broader trend towards adaptable laboratory technologies, aiming to address the unique configurations and spatial requirements of diverse medical settings. This flexibility opens the door for enhanced operational efficiencies in labs that have previously struggled with standardized workflows.
Global Demand for Advanced Diagnostic Solutions
The positive reception of the CURECATM concept video and the overall vision of the platform signal a strong demand for next-generation diagnostic solutions worldwide. Seegene's CEO, Jong-Yoon Chun, noted the importance of this feedback and its implication for future product enhancements. He stated, "The enthusiastic global response to our concept video and vision for CURECATM demonstrate the strong demand for next-generation diagnostic solutions."
Backed by over two decades of experience in the molecular diagnostics field, particularly highlighted during the COVID-19 pandemic, Seegene is set to leverage its formidable expertise to propel CURECATM into the forefront of laboratory automation. The initiative aims not only to improve efficiencies in laboratories but pave the way for an era free of diseases through advanced diagnostic capabilities.
Conclusion
As laboratories worldwide increasingly seek efficiencies and improved workflows, CURECATM stands out as a promising solution. With its potential to automate complex processes and reduce reliance on manual handling, this cutting-edge system could reshape the future of PCR diagnostics. By transforming laboratory operations, Seegene is poised to remain at the helm of innovation in the realm of molecular diagnostics, ultimately contributing to enhanced healthcare outcomes and disease management.